John Schmedtje, MD
Cardiovascular Disease · Roanoke, VANPI 1093856023
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $2,030 of the $2,950 with a category attached, or 68.8%. 4 manufacturers reported payments, led by Novartis at 48.3% of the total. Reporting peaked in 2023 at $2,668 and has fallen 94.1% since, to $157 in 2024.
Across 16 payments — averaging $184.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$1K
- Janssen Research & Development, LLC$1K
- Kiniksa Pharmaceuticals International, PLC$124
- Novo Nordisk$32
Across 393 payments — averaging $3512.26 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$530K
- GE HealthCare$276K
- Janssen Research & Development, LLC$272K
- Boehringer Ingelheim International GmbH$98K
- Boehringer Ingelheim Pharma GmbH & Co.kg$63K
- Amgen$51K
- plus $91K from 5 others
What the payments were for
- Travel & lodging$2,03069%
- Food & beverage$88730%
- Education$321%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 6 | $1,426 |
| Janssen Research & Development, LLC | 8 | $1,367 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $124 |
| Novo Nordisk | 1 | $32 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LEQVIO$1,404
How this compares
$2,950 in reported general payments places this provider in the 65th percentile of 548 cardiovascular disease providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 131 | $129,300 |
| VascepaIcosapent Ethyl | 12 | $9,070 |
| Metoprolol Succinate | 240 | $2,290 |
| Losartan Potassium | 260 | $1,785 |
| Potassium Chloride | 45 | $1,694 |
| Atorvastatin Calcium | 266 | $1,637 |
| Amlodipine Besylate | 264 | $1,369 |
| Prasugrel Hcl | 21 | $1,087 |
| Nitroglycerin | 77 | $767 |
| Lisinopril | 98 | $682 |
| SotalolSotalol Hcl | 18 | $678 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 71 | $574 |
| ClopidogrelClopidogrel Bisulfate | 40 | $523 |
| Minoxidil | 25 | $443 |
| Pravastatin Sodium | 32 | $390 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Roanoke
- Patrick KietrsunthornRoanoke$43K
- Cynthia PhilipRoanoke$41K
- Faisal AslamRoanoke$20K
- Owusu AsamoahRoanoke$18K
- George VetrovecRichmond$2.3M
- Hamid TaheriManassas$501K
- Cyrus HadadiNorfolk$360K
- Michael AyersCharlottesville$305K
- David LimCharlottesville$264K
- Alexander TruesdellFalls Church$167K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.